CL2021000196A1 - Método de tratamiento de la epilepsia - Google Patents

Método de tratamiento de la epilepsia

Info

Publication number
CL2021000196A1
CL2021000196A1 CL2021000196A CL2021000196A CL2021000196A1 CL 2021000196 A1 CL2021000196 A1 CL 2021000196A1 CL 2021000196 A CL2021000196 A CL 2021000196A CL 2021000196 A CL2021000196 A CL 2021000196A CL 2021000196 A1 CL2021000196 A1 CL 2021000196A1
Authority
CL
Chile
Prior art keywords
fenfluramine
epileptic seizure
racemate
treatment
preferred embodiments
Prior art date
Application number
CL2021000196A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey Paul Bechard
Robin Paul Sherrington
Jean-Jacques Alexandre Cadieux
Parisa Karimi Tari
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CL2021000196A1 publication Critical patent/CL2021000196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2021000196A 2018-07-27 2021-01-25 Método de tratamiento de la epilepsia CL2021000196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862711051P 2018-07-27 2018-07-27

Publications (1)

Publication Number Publication Date
CL2021000196A1 true CL2021000196A1 (es) 2021-12-31

Family

ID=67551433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000196A CL2021000196A1 (es) 2018-07-27 2021-01-25 Método de tratamiento de la epilepsia

Country Status (20)

Country Link
US (1) US12558326B2 (cg-RX-API-DMAC7.html)
EP (1) EP3829558B1 (cg-RX-API-DMAC7.html)
JP (1) JP2021530541A (cg-RX-API-DMAC7.html)
KR (1) KR20210061332A (cg-RX-API-DMAC7.html)
CN (1) CN112930175A (cg-RX-API-DMAC7.html)
AU (1) AU2019310600A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001135A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106031A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000196A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021002087A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210095A (cg-RX-API-DMAC7.html)
EA (1) EA202190369A1 (cg-RX-API-DMAC7.html)
ES (1) ES2988130T3 (cg-RX-API-DMAC7.html)
IL (1) IL280128A (cg-RX-API-DMAC7.html)
MA (1) MA53329A (cg-RX-API-DMAC7.html)
MX (1) MX2021000987A (cg-RX-API-DMAC7.html)
PE (1) PE20211065A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550176A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100682YA (cg-RX-API-DMAC7.html)
WO (1) WO2020023923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
DK3800177T3 (da) 2015-12-22 2025-03-31 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
MA53488A (fr) * 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
EP3999570A1 (en) * 2019-07-18 2022-05-25 Basf Se Allophanate based dispersing agent
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023034115A1 (en) * 2021-09-01 2023-03-09 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (cg-RX-API-DMAC7.html) 1960-11-05
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
ATE199829T1 (de) * 1994-06-03 2001-04-15 Thejmde Trust Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6591909B1 (en) 2001-12-20 2003-07-15 Halliburton Energy Services, Inc. Whey protein retarder
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3035926T3 (da) * 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK3261640T3 (da) * 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的5−ht受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
JP2017051788A (ja) 2016-12-21 2017-03-16 株式会社三洋物産 遊技機
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
CA3106031A1 (en) 2020-01-30
WO2020023923A1 (en) 2020-01-30
EP3829558C0 (en) 2024-07-03
SG11202100682YA (en) 2021-02-25
MX2021000987A (es) 2021-06-15
ES2988130T3 (es) 2024-11-19
IL280128A (en) 2021-03-01
BR112021001135A2 (pt) 2021-04-20
KR20210061332A (ko) 2021-05-27
US12558326B2 (en) 2026-02-24
CO2021002087A2 (es) 2021-04-30
US20200030260A1 (en) 2020-01-30
EP3829558A1 (en) 2021-06-09
CR20210095A (es) 2021-06-01
PH12021550176A1 (en) 2021-10-11
EA202190369A1 (ru) 2021-06-10
CN112930175A (zh) 2021-06-08
JP2021530541A (ja) 2021-11-11
MA53329A (fr) 2022-03-02
PE20211065A1 (es) 2021-06-09
EP3829558B1 (en) 2024-07-03
AU2019310600A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
CO2021002087A2 (es) Método para tratar la epilepsia
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
MX2024002904A (es) Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.
CY1125071T1 (el) Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
CL2021003134A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
JOP20220061A1 (ar) علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي
BR112018004680A2 (pt) método de tratamento de distúrbios de desenvolvimento
MX2019001036A (es) Tratamiento y prevencion de los trastornos del sueño.
EA202091057A2 (ru) Способы и композиции для лечения нарушений, ассоциированных со старением
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201991643A1 (ru) Человеческие антитела к токсину гемолизину а s.aureus
MX2017013852A (es) Produccion escalable de vesiculas extracelulares estandarizadas, preparaciones de vesiculas extracelular y usos de estos.
MX2022012366A (es) Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas.
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
DOP2011000209A (es) Compuestos de quinazolina sustituidos
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
JOP20220310A1 (ar) علاج اضطراب طيف التوحد بكانابيديول
EA202091527A1 (ru) Лечение автономных нарушений с помощью ботулинового токсина
CO2024011399A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
EA202092472A1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.